Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2016 (2016), Article ID 5797804, 5 pages
http://dx.doi.org/10.1155/2016/5797804
Research Article

Use of Serotonergic Drugs in Canada for Gastrointestinal Motility Disorders: Results of a Retrospective Cohort Study

Schulich School of Medicine & Dentistry, University Hospital, Western University, Rm C8-114, 339 Windermere Road, London, ON, Canada N6A 5A5

Received 27 December 2015; Revised 10 March 2016; Accepted 5 April 2016

Academic Editor: Anna P. Malykhina

Copyright © 2016 Biniam Kidane et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Sandler, “Epidemiology of irritable bowel syndrome in the United States,” Gastroenterology, vol. 99, no. 2, pp. 409–415, 1990. View at Google Scholar · View at Scopus
  2. R. S. Sandler, J. E. Everhart, M. Donowitz et al., “The burden of selected digestive diseases in the United States,” Gastroenterology, vol. 122, no. 5, pp. 1500–1511, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. B. M. R. Spiegel, “The burden of IBS: looking at metrics,” Current Gastroenterology Reports, vol. 11, no. 4, pp. 265–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Drossman, “Introduction. The Rome Foundation and Rome III,” Neurogastroenterology & Motility, vol. 19, no. 10, pp. 783–786, 2007. View at Publisher · View at Google Scholar
  5. J. H. Pemberton, D. M. Rath, and D. M. Ilstrup, “Evaluation and surgical treatment of severe chronic constipation,” Annals of Surgery, vol. 214, no. 4, pp. 403–413, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. G. P. FitzHarris, J. Garcia-Aguilar, S. C. Parker et al., “Quality of life after subtotal colectomy for slow-transit constipation: both quality and quantity count,” Diseases of the Colon and Rectum, vol. 46, no. 4, pp. 433–440, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Smalley, D. Shatin, D. K. Wysowski et al., “Contraindicated use of cisapride: impact of food and drug administration regulatory action,” The Journal of the American Medical Association, vol. 284, no. 23, pp. 3036–3039, 2000. View at Publisher · View at Google Scholar
  8. US Food and Drug Administration, “FDA Announces Discontinued Marketing of GI Drug, Zelnorm, for Safety Reasons,” 2007, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108879.htm.
  9. J. Tack, S. Müller-Lissner, P. Bytzer et al., “A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation,” Gut, vol. 54, no. 12, pp. 1707–1713, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Kidane, J. Lam, F. Manji, V. Gupta, S. A. Chadi, and B. M. Taylor, “Histological findings in resected bowel of motility-disordered patients,” American Surgeon, vol. 81, no. 2, pp. 187–192, 2015. View at Google Scholar · View at Scopus
  11. J. Kellow, O. Y. Lee, F. Y. Chang et al., “An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome,” Gut, vol. 52, no. 5, pp. 671–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Nyhlin, C. Bang, L. Elsborg et al., “A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome,” Scandinavian Journal of Gastroenterology, vol. 39, no. 2, pp. 119–126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. World Gastroenterology Organisation, World Gastroenterology Organisation Global Guidelines. Constipation: A Global Perspective, World Gastroenterology Organisation, 2010.
  14. National Institute for Health and Clinical Excellence, NICE Technology Appraisal Guidance (TA211). Prucalopride for the treatment of Chronic Constipation in Women, National Institute for Health and Clinical Excellence, London, UK, 2010.
  15. J. L. Anderson, H. T. May, T. L. Bair, J. B. Muhlestein, B. D. Horne, and J. F. Carlquist, “Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 14, no. 3, pp. 170–175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Loughlin, S. Quinn, E. Rivero et al., “Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 15, no. 2, pp. 151–157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Wysowski, A. Corken, H. Gallo-Torres et al., “Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions,” The American Journal of Gastroenterology, vol. 96, pp. 1698–1703, 2001. View at Publisher · View at Google Scholar
  18. J. Y. Lam, B. Kidane, F. Manji, and B. M. Taylor, “Improved health-related quality of life after surgical management of severe refractory constipation-dominant irritable bowel syndrome,” International Surgery, vol. 100, no. 1, pp. 63–69, 2015. View at Publisher · View at Google Scholar
  19. D. C. N. K. Nyam, J. H. Pemberton, D. M. Ilstrup, and D. M. Rath, “Long-term results of surgery for chronic constipation,” Diseases of the Colon and Rectum, vol. 40, no. 3, pp. 273–279, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. C. H. Knowles, M. Scott, and P. J. Lunniss, “Outcome of colectomy for slow transit constipation,” Annals of Surgery, vol. 230, no. 5, pp. 627–638, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. D. E. Beck, F. G. Opelka, H. R. Bailey, S. M. Rauh, and C. L. Pashos, “Incidence of small-bowel obstruction and adhesiolysis after open colorectal and general surgery,” Diseases of the Colon and Rectum, vol. 42, no. 2, pp. 241–248, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. C. R. Chapman and G. B. Cox, “Anxiety, pain, and depression surrounding elective surgery: a multivariate comparison of abdominal surgery patients with kidney donors and recipients,” Journal of Psychosomatic Research, vol. 21, no. 1, pp. 7–15, 1977. View at Publisher · View at Google Scholar · View at Scopus
  23. US Food and Drug Administration, Zelnorm (Tegaserod Maleate) Information, US Food and Drug Administration, Silver Spring, Md, USA, 2012, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm.
  24. Health Canada, Voluntary Suspension of Sales of Zelnorm due to Cardiovascular Ischemic Events, Health Canada, 2007, http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2007/zelnorm_hpc-cps_2-eng.php.